Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced it will report financial results and operational highlights for the second quarter of 2026 before hosting a conference call and webcast at 8:30 a.m. ET on Aug. 10, 2026. The announcement, detailed in a press release available at https://ibn.fm/A9CfR, underscores the company's ongoing commitment to advancing treatments for central nervous system (CNS) and immunology conditions with high unmet medical need.
The second-quarter update comes as Tonix continues to commercialize TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The company's CNS commercial infrastructure supports its marketed products, including Zembrace® SymTouch® and Tosymra® for acute migraine. Additionally, Tonix is evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, expanding its potential beyond fibromyalgia.
Beyond its commercial portfolio, Tonix is advancing a robust pipeline. TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, addresses a rare disease with no approved therapies. In immunology, TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection, represent significant opportunities. These programs highlight Tonix's focus on areas where current treatments are limited or nonexistent.
The financial results will provide investors with insights into the company's revenue from TONMYA and its migraine products, as well as research and development expenditures. This transparency is crucial for stakeholders assessing Tonix's path to profitability and its ability to sustain pipeline development.
A replay of the webcast will be available in the Investors section of the company's website following the event. Investors and analysts can access the live call to gain a deeper understanding of Tonix's strategic direction. The company's newsroom, accessible at https://ibn.fm/TNXP, offers additional updates and resources.
Tonix's progress is particularly significant given the high unmet need in fibromyalgia, where TONMYA offers a new mechanism of action. If successful in Phase 2 trials, the drug could address depression and stress disorders, expanding its market. Similarly, TNX-4800 and TNX-1500 target large patient populations: Lyme disease affects hundreds of thousands annually, and kidney transplant rejection remains a major challenge. The upcoming call will likely elaborate on these opportunities and any regulatory milestones.
